|
|
||||||||
| Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology. |
Departments of Neurology and Neurosurgery and Histology, Neuroscience Center (Drs. Obeso, Rodriguez-Oroz, Alonso, Zamarbide and Lanciego), FIMA, Clinica Universitaria and Medical School, University of Navarra, Pamplona, Spain; Experimental Neurology Laboratory, Fundacio Clinic-Hospital Clinic (Dr. Marin), IDIBAG, Barcelona, Spain; and Department of Physiology, Medical School (Dr. Rodriguez-Diaz), University of La Laguna, Tenerife, Spain.
Address correspondence and reprint requests to Dr. Jose Obeso, Neurologia-Neurociencias, Clinica Universitaria, Avenida Pio XII 36, Pamplona 31180, Spain.
The severity of dopamine depletion and the consequent pathophysiologic changes that occur in basal ganglia circuits determine the severity of parkinsonian signs. Restoring the dopamine deficit or the downstream physiologic abnormalities improves Parkinsons Disease (PD) main motor features and as a result, attenuates the short-duration response (SDR). Therefore, both the magnitude and duration of the motor response are a function of the degree of motor severity, which is primarily governed by the loss of tonic dopaminergic activity and disruption of basal ganglia homeostatic mechanisms among which the STN-GPe/GPi circuits play a fundamental role. As neurodegeneration advances, standard levodopa administration give rises to wider oscillations in striatal dopamine availability and "pulsatile" stimulation of striatal dopamine receptors becomes predominant. This induces molecular and physiologic changes that further accentuate and aggravate the SDR that sustains motor fluctuations. Treatments capable of providing and restoring more tonic and physiologic dopaminergic stimulation may avoid many of these abnormalities and lead to better clinical outcomes.
1Present address: Servicio de Neurologia, Fundacion Jimenez Diaz, Clinica de la Concepcion, Madrid, Spain.
This article has been cited by other articles:
![]() |
O.K. Sujith and C. Lane Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 105 - 113. [Abstract] [PDF] |
||||
![]() |
I. Morales, J. G. Dopico, M. Sabate, T. Gonzalez-Hernandez, and M. Rodriguez Substantia nigra osmoregulation: taurine and ATP involvement Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1934 - C1941. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Androulidakis, A. A. Kuhn, C. Chu Chen, P. Blomstedt, F. Kempf, A. Kupsch, G.-H. Schneider, L. Doyle, P. Dowsey-Limousin, M. I. Hariz, et al. Dopaminergic therapy promotes lateralized motor activity in the subthalamic area in Parkinson's disease Brain, February 1, 2007; 130(2): 457 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. McGregor and J. Wheless Pediatric Experience With Sudden Unexplained Death in Epilepsy at a Tertiary Epilepsy Center J Child Neurol, September 1, 2006; 21(9): 782 - 787. [Abstract] [PDF] |
||||
![]() |
F. Alonso-Frech, I. Zamarbide, M. Alegre, M. C. Rodriguez-Oroz, J. Guridi, M. Manrique, M. Valencia, J. Artieda, and J. A. Obeso Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease Brain, July 1, 2006; 129(7): 1748 - 1757. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Sheth and B. E. Gidal Topical Review: Optimizing Epilepsy Management in Teenagers J Child Neurol, April 1, 2006; 21(4): 273 - 279. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |